Independent Predictors and Causes of Thirty-Day Gastrointestinal Readmissions Following COVID-19-Related Hospitalizations: Analysis of the National Readmission Database.
30-day readmission
Acute pancreatitis
COVID-19
GI bleeding
Intestinal obstruction
Journal
Gastroenterology research
ISSN: 1918-2805
Titre abrégé: Gastroenterology Res
Pays: Canada
ID NLM: 101519422
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
30
03
2023
accepted:
02
05
2023
medline:
23
6
2023
pubmed:
23
6
2023
entrez:
23
6
2023
Statut:
ppublish
Résumé
The coronavirus disease 2019 (COVID-19) pandemic led to significant mortality and morbidity in the United States. The burden of COVID-19 was not limited to the respiratory tract alone but had significant extrapulmonary manifestations. We decided to examine the causes, predictors, and outcomes of gastrointestinal (GI)-related causes of 30-day readmission following index COVID-19 hospitalization. We used the National Readmission Database (NRD) from 2020 to identify hospitalizations among adults with principal diagnosis of COVID-19. We identified GI-related hospitalizations within 30 days of index admission after excluding elective and traumatic admissions. We identified the top causes of GI-related readmission, and the outcomes of these hospitalizations. We used a multivariate Cox regression analysis to identify the independent predictors of readmission. Among 1,024,492 index hospitalizations with a primary diagnosis of COVID-19 in the 2020 NRD database, 644,903 were included in the 30-day readmission study. Of these 3,276 (0.5%) were readmitted in 30 days due to primary GI causes. The top five causes of readmissions we identified in this study were GI bleeding, intestinal obstruction, acute diverticulitis, acute pancreatitis, and acute cholecystitis. Multivariate Cox regression analysis done adjusting for confounders showed that renal failure, alcohol abuse, and peptic ulcer disease were associated with increased odds of 30-day readmission from GI-related causes. GI manifestations of COVID-19 are not uncommon and remain an important cause of readmission. Targeted interventions addressing the modifiable predictors of readmission identified will be beneficial in reducing the burden on already limited healthcare resources.
Sections du résumé
Background
UNASSIGNED
The coronavirus disease 2019 (COVID-19) pandemic led to significant mortality and morbidity in the United States. The burden of COVID-19 was not limited to the respiratory tract alone but had significant extrapulmonary manifestations. We decided to examine the causes, predictors, and outcomes of gastrointestinal (GI)-related causes of 30-day readmission following index COVID-19 hospitalization.
Methods
UNASSIGNED
We used the National Readmission Database (NRD) from 2020 to identify hospitalizations among adults with principal diagnosis of COVID-19. We identified GI-related hospitalizations within 30 days of index admission after excluding elective and traumatic admissions. We identified the top causes of GI-related readmission, and the outcomes of these hospitalizations. We used a multivariate Cox regression analysis to identify the independent predictors of readmission.
Results
UNASSIGNED
Among 1,024,492 index hospitalizations with a primary diagnosis of COVID-19 in the 2020 NRD database, 644,903 were included in the 30-day readmission study. Of these 3,276 (0.5%) were readmitted in 30 days due to primary GI causes. The top five causes of readmissions we identified in this study were GI bleeding, intestinal obstruction, acute diverticulitis, acute pancreatitis, and acute cholecystitis. Multivariate Cox regression analysis done adjusting for confounders showed that renal failure, alcohol abuse, and peptic ulcer disease were associated with increased odds of 30-day readmission from GI-related causes.
Conclusions
UNASSIGNED
GI manifestations of COVID-19 are not uncommon and remain an important cause of readmission. Targeted interventions addressing the modifiable predictors of readmission identified will be beneficial in reducing the burden on already limited healthcare resources.
Identifiants
pubmed: 37351083
doi: 10.14740/gr1623
pmc: PMC10284648
doi:
Types de publication
Journal Article
Langues
eng
Pagination
157-164Informations de copyright
Copyright 2023, Kwei-Nsoro et al.
Déclaration de conflit d'intérêts
None to declare.
Références
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Ann Med Surg (Lond). 2020 Dec;60:434-437
pubmed: 33224493
Cureus. 2021 Feb 22;13(2):e13490
pubmed: 33777577
Cureus. 2022 Jul 19;14(7):e27043
pubmed: 35989841
Obesity (Silver Spring). 2020 Jul;28(7):1187-1190
pubmed: 32339391
Gastroenterol Hepatol Bed Bench. 2020 Fall;13(4):410-414
pubmed: 33244387
Front Endocrinol (Lausanne). 2022 Jun 03;13:780872
pubmed: 35721716
Biochem Biophys Res Commun. 2020 May 21;526(1):135-140
pubmed: 32199615
Aliment Pharmacol Ther. 2014 Feb;39(4):359-70
pubmed: 24387341
Cureus. 2021 Apr 26;13(4):e14687
pubmed: 34055531
Saudi J Kidney Dis Transpl. 2016 Jul-Aug;27(4):748-51
pubmed: 27424692
Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1735-1743
pubmed: 27515592
J Transl Sci. 2017 May;3(3):
pubmed: 30221012
Can J Gastroenterol Hepatol. 2021 Sep 1;2021:2534975
pubmed: 34513750
J Transl Int Med. 2021 Mar 31;9(1):59-60
pubmed: 33850804
World J Gastroenterol. 2007 Aug 7;13(29):3985-9
pubmed: 17663515
Am J Med. 1988 Dec;85(6):806-10
pubmed: 3264111
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):644-645
pubmed: 32339473
Cureus. 2021 Jun 23;13(6):e15870
pubmed: 34327095
Cureus. 2021 Feb 9;13(2):e13236
pubmed: 33728185
Curr Cardiol Rev. 2019;15(1):55-63
pubmed: 29992892
Braz J Infect Dis. 2020 Nov - Dec;24(6):561-564
pubmed: 32961108
Proc (Bayl Univ Med Cent). 2023 Jan 9;36(2):145-150
pubmed: 36876259
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Mucosal Immunol. 2009 Mar;2(2):100-2
pubmed: 19129753
Cureus. 2023 Jan 2;15(1):e33252
pubmed: 36741637
Cureus. 2021 Jun 3;13(6):e15431
pubmed: 34258107
Proc (Bayl Univ Med Cent). 2022 Aug 11;35(6):768-772
pubmed: 36304619
Transplant Proc. 2021 May;53(4):1215-1218
pubmed: 33678444
J Hepatol. 2020 Dec;73(6):1566-1568
pubmed: 32890595
Life (Basel). 2020 Nov 23;10(11):
pubmed: 33238410
J Pathol. 2004 Jun;203(2):622-30
pubmed: 15141376
Semin Dial. 2006 Jul-Aug;19(4):317-22
pubmed: 16893410
Gastroenterology Res. 2022 Oct;15(5):253-262
pubmed: 36407807
Cureus. 2021 Mar 15;13(3):e13901
pubmed: 33880257
Health Aff (Millwood). 2019 Apr;38(4):585-593
pubmed: 30933582
J Gastrointest Surg. 2020 Dec;24(12):2888-2889
pubmed: 32363540
Nat Med. 2020 Jul;26(7):1017-1032
pubmed: 32651579